Open AccessTRITON and Beyond: New Insights into the Profile of Prasugrel
Author(s) -
Jakubowski Joseph A.,
Riesmeyer Jeffrey S.,
Close Sandra L.,
Leishman Amy G.,
Erlinge David
Publication year - 2012
Publication title -
cardiovascular therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 46
eISSN - 1755-5922
pISSN - 1755-5914
DOI - 10.1111/j.1755-5922.2011.00263.x
Subject(s) - prasugrel , thienopyridine , medicine , clopidogrel , timi , thrombolysis , myocardial infarction , cardiology
Summary Prasugrel, a third‐generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON‐TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON‐TIMI 38 (TRITON) study primary disclosure.